The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

The number of diagnosed prevalent drug-treated mHSPC cases in the 8MM will rise from 196,867 in 2025 to 244,101 by 2033.

While established US biotech hubs may still rule the roost, emerging competitors are looking to grab a larger slice of the ...

The AAM’s Giuseppe Randazzo warns that the generics business could become unsustainable in the future if the market dynamics ...

France-based Adcytherix has completed a Series A funding round, raising €105m ($122m) earmarked for expediting the ADC ...

With a legacy rooted in global scientific excellence, Sweden is quietly building one of Europe’s most dynamic biotech ...

Oceanpine Capital is to acquire an 80% equity stake in Beijing Jacoray Pharmaceutical Technology for 200m yuan ($28m).

EMD Serono has partnered the Trump administration to expand access to the company’s in vitro fertilisation (IVF) therapies.

Clinical research organizations (CROs) have transformed into major strategic partners for biotechnology and pharmaceutical ...

The WHO calls for increased policy focus on neurological disorders like Alzheimer’s disease, an indication that has seen ...

AstraZeneca has unveiled a newly expanded manufacturing facility in Texas to the tune of $445m, as the drugmaker aims to meet ...